Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan dura gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - Клопидогрел prikazan odrasle za prevenciju атеротромботических događaja:pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - abirateron acetat - prostatske neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan s.a.s - ribavirin - hepatitis c, kronični - antivirusni lijekovi za sustavnu uporabu - ribavirin mylan je indiciran za liječenje kroničnog hepatitisa c i mora se koristiti samo kao dio kombiniranom s interferonom alfa-2b (odrasli, djeca (u dobi od tri ili više godina) i adolescente). ribavirin monoterapija se ne smije koristiti. ne postoji sigurnost ili učinkovitost primjene informacijskih рибавирина s drugim oblicima interferona (ja. ne alfa-2b). molimo, molimo, takođe pročitajte i s interferonom alfa-2b kratak opis robe (Смпц) za прописывания informacije određene proizvode. naivno patientsadult patientsribavirin mylan navedene u kombinaciji s interferonom alfa-2b, za liječenje odraslih bolesnika sa svim vrstama kroničnog hepatitisa c, osim genotip 1, prethodno obrađene, bez декомпенсации jetre, povećane razine аланинаминотрансферазы (alt), koji su pozitivni za serumu hepatitisa b-s-virus (hcv) rna. djeca i adolescentsribavirin mylan u drugačije, na način kombinaciji s interferonom alfa-2b, za liječenje djece i adolescenata u dobi od tri godine i stariji, koji imaju sve vrste kroničnog hepatitisa c, osim genotip 1, prethodno obrađene, bez jetre декомпенсация, i koje su pozitivne u serumu rnk hcv. odlučujući neće odgoditi liječenje do odrasle dobi, važno je uzeti u obzir da je kombinirana terapija uzrokuje zadržavanje rasta . Обратимость inhibicije rasta povjerenja. odluka mora biti donesena na individualnoj osnovi (vidi odjeljak 4. prethodno liječenje-odricanje patientsadult patientsribavirin mylan navedene u kombinaciji s interferonom alfa-2b, za liječenje odraslih bolesnika s kroničnim hepatitisom c koji su prethodno odgovorili (sa normalizaciji alt na kraju tretmana) s interferonom alfa kao monoterapija, ali se naknadno ponavljanje.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan pharmaceuticals limited - rasagilin tartarat - parkinsonova bolest - antiparkinsonski lijekovi - rasagiline mylan je indiciran za liječenje idiopatska parkinsonova bolest (pd) kao monoterapija (bez levodope) ili kao dodatak terapija (s levodopom) u bolesnika s kraja doze fluktuacije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan pharmaceuticals limited - febuxostat - hyperuricemia; arthritis, gouty; gout - antigadni pripravci - febuxostat mylan je indiciran za prevenciju i liječenje hiperuricemija u odraslih bolesnika podvrgnutih kemoterapijom zbog zloćudne hematološke bolesti u srednje do visoke opasnosti od tumora lize sindrom (tls). Фебуксостат mylan u indiciran za liječenje kronične hiperurikemijom u uvjetima kada уратные naslage već došlo (uključujući i osobnu povijest, ili dostupnost, отложении soli i/ili nadut artritisa). Фебуксостат mylan u indiciran za odrasle.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. trostruki kombinovanu terapiju) kao dodatak prehrani i vježbe kod pacijenata, nedovoljno kontroliranim o njihovo maksimalno переносимой doze метформина i sulfonilurejom. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan s.a.s. - docetaksel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastična sredstva - liječenje raka dojke, posebni oblici raka pluća (karcinom pluća ne-malih stanica), rak prostate, rak želuca ili rak glave i vrata.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan pharmaceuticals limited - besilate amlodipin, валсартан - hipertenzija - sredstva koja djeluju na sustav renin-angiotenzina - liječenje esencijalne hipertenzije. amlodipin/Валсартан mylan navedene u odraslih, kod kojih je krvni pritisak nije dovoljno prati na amlodipin ili валсартан kao monoterapija.